NeoGenomics (NEO) Tops Q3 EPS by 3c, Beats on Revenues; Lifts FY18 EPS/Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
NeoGenomics Reports 17% Revenue Growth to Record $69 Million
October 30, 2018 7:00 AM EDTFT. MYERS, Fla., Oct. 30, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2018.
Third Quarter 2018 Highlights:
  17% increase in consolidated revenueÂ
  14% increase in clinical genetic testing volume(1)
  21% increase in Pharma Services revenue; 75% increase in Pharma Services backlog
  Completed $135 million, net equity offering
  Announced acquisition of Genoptix in October for $125 million in cash and 1 million shares of NeoGenomics common... More
